In:
Cancer, Wiley, Vol. 128, No. 5 ( 2022-03), p. 1057-1065
Abstract:
The addition of doxorubicin to the previous standard regimen of cisplatin, 5‐flourouracil, and vincristine is a feasible, tolerable, and efficacious novel treatment regimen (cisplatin, 5‐flourouracil, vincristine, and doxorubicin). This regimen is a reasonable option for future clinical trials, especially those including patients with unresectable disease at diagnosis.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink